Drug intelligence / Profile preview

PEARL-201

Development stage: Preclinical
Lead developer: PearlsInMires
Modality: Small Molecules

Overview

PEARL-201 is a preclinical-stage small molecule therapeutic being developed by PearlsInMires for the treatment of alopecia. It is designed to target the androgen receptor (AR) and dihydrotestosterone (DHT) signaling pathway, which plays a critical role in the miniaturization of hair follicles in androgenetic alopecia. By modulating these androgenic components, PEARL-201 aims to prevent hair loss and potentially promote hair regrowth. The program is currently in the preclinical phase, with the developer aiming to complete patent applications for this and related assets by 2025.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on PEARL-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEARL-201.

Explore the full profile